<DOC>
	<DOCNO>NCT01278030</DOCNO>
	<brief_summary>The purpose study demonstrate cardiac resynchronization therapy ( CRT ) responder rate improve 3-dimensional ( 3D ) echo-guided left ventricular ( LV ) lead placement compare traditional LV lead placement .</brief_summary>
	<brief_title>Real Time 3-Dimensional Echocardiography Left Ventricular Lead Site Selection Reduce Cardiac Resynchronization Therapy Non-Responder Rates</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Patients implanted FDA approve St. Jude Medical CRTD device ( i.e . PROMOTEÂ® new device similar functionality ) Patients approved indication per American College Cardiology/American Heart Association/Heart Rhythm Society guideline implantation CRTD Patients receive new implant upgrade exist pacemaker Implantable Cardiovertor Defibrillator prior Left Ventricular lead placement Patients must sinus rhythm time enrollment visit baseline measurement Persistent permanent atrial fibrillation Heart transplantation Recent myocardial infarction ( &lt; 90 day ) Contraindication contrast agent Are less 18 year age Are pregnant Are currently participate clinical investigation include active treatment arm Have life expectancy le 6 month</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>